The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd..
BACKGROUND: The NAPOLI-I trial showed better outcome of nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) compared to 5-FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine-based therapy. This study aims to explore the real-world efficacy and safety of 5-FU/LV-nal-IRI.
METHODS: This is a retrospective multicenter analysis including advPDAC patients receiving 5-FU/LV-nal-IRI after failure of gemcitabine-based therapy. Survival analyses were performed using Kaplan-Meier method, univariate and multivariate analyses by Cox regression.
RESULTS: A total of 296 patients (median age 64.4 years, ECOG PS ≥1 in 56% of cases) were treated at 11 Italian institutions between 2016 and 2018. 34% of them underwent primary tumor resection, and 79% received gemcitabine-nabpaclitaxel as first line. 5-FU/LV-nal-IRI was administered as second-line in 73% of cases. Objective response and disease control rate were 12% and 41%, respectively. Treatment was well tolerated with dose reductions in 50% of patients but no one permanent discontinuation; the commonest grade ≥3 toxicities were neutropenia (14%) and diarrhea (12%). Median PFS and OS from 5-FU/LV-nal-IRI initiation was 3.2 and 7.1 months, respectively.
CONCLUSIONS: These real-world data confirm the 5-FU/LV-nal-IRI efficacy and safety in advPDAC patients progressed to gemcitabine-based therapy, with outcomes comparable to NAPOLI-1, even in a less-selected population and with more modern therapeutic algorithm.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cancer medicine - 12(2023), 13 vom: 01. Juli, Seite 14337-14345 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Procaccio, Letizia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7673326042 |
|---|
| Anmerkungen: |
Date Completed 21.07.2023 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cam4.6111 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357803353 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357803353 | ||
| 003 | DE-627 | ||
| 005 | 20231227131311.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cam4.6111 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM357803353 | ||
| 035 | |a (NLM)37278395 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Procaccio, Letizia |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: The NAPOLI-I trial showed better outcome of nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) compared to 5-FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine-based therapy. This study aims to explore the real-world efficacy and safety of 5-FU/LV-nal-IRI | ||
| 520 | |a METHODS: This is a retrospective multicenter analysis including advPDAC patients receiving 5-FU/LV-nal-IRI after failure of gemcitabine-based therapy. Survival analyses were performed using Kaplan-Meier method, univariate and multivariate analyses by Cox regression | ||
| 520 | |a RESULTS: A total of 296 patients (median age 64.4 years, ECOG PS ≥1 in 56% of cases) were treated at 11 Italian institutions between 2016 and 2018. 34% of them underwent primary tumor resection, and 79% received gemcitabine-nabpaclitaxel as first line. 5-FU/LV-nal-IRI was administered as second-line in 73% of cases. Objective response and disease control rate were 12% and 41%, respectively. Treatment was well tolerated with dose reductions in 50% of patients but no one permanent discontinuation; the commonest grade ≥3 toxicities were neutropenia (14%) and diarrhea (12%). Median PFS and OS from 5-FU/LV-nal-IRI initiation was 3.2 and 7.1 months, respectively | ||
| 520 | |a CONCLUSIONS: These real-world data confirm the 5-FU/LV-nal-IRI efficacy and safety in advPDAC patients progressed to gemcitabine-based therapy, with outcomes comparable to NAPOLI-1, even in a less-selected population and with more modern therapeutic algorithm | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Irinotecan |2 NLM | |
| 650 | 7 | |a 7673326042 |2 NLM | |
| 650 | 7 | |a Leucovorin |2 NLM | |
| 650 | 7 | |a Q573I9DVLP |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 650 | 7 | |a Gemcitabine |2 NLM | |
| 650 | 7 | |a Camptothecin |2 NLM | |
| 650 | 7 | |a XT3Z54Z28A |2 NLM | |
| 700 | 1 | |a Merz, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Fasano, Morena |e verfasserin |4 aut | |
| 700 | 1 | |a Vaccaro, Vanja |e verfasserin |4 aut | |
| 700 | 1 | |a Giommoni, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Pretta, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Noventa, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Satolli, Maria Antonietta |e verfasserin |4 aut | |
| 700 | 1 | |a Giordano, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Zichi, Clizia |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Carmine |e verfasserin |4 aut | |
| 700 | 1 | |a Zecchetto, Camilla |e verfasserin |4 aut | |
| 700 | 1 | |a Barsotti, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a De Vita, Ferdinando |e verfasserin |4 aut | |
| 700 | 1 | |a Milella, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Antonuzzo, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Scartozzi, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Zaniboni, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Spadi, Rosella |e verfasserin |4 aut | |
| 700 | 1 | |a Casalino, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Bergamo, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a De Toni, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Melisi, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Lonardi, Sara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer medicine |d 2012 |g 12(2023), 13 vom: 01. Juli, Seite 14337-14345 |w (DE-627)NLM224388460 |x 2045-7634 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:13 |g day:01 |g month:07 |g pages:14337-14345 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cam4.6111 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 13 |b 01 |c 07 |h 14337-14345 | ||